Golidocitinib in Combination With Sintilimab for PD-L1 Selected Treatment Locally Advanced or Metastatic Non-Small Cell Lung Cancer(NSCLC)

Conditions: Non-Small-Cell Lung Cancer Interventions: Drug: Golidocitinib; Drug: Sintilimab; Drug: platinum doublet chemotherapy Sponsors: Cancer Institute and Hospital, Chinese Academy of Medical Sciences; Dizal Pharmaceuticals Not yet recruiting

https://clinicaltrials.gov/study/NCT06198907

Source: ClinicalTrials.gov - January 10, 2024 Category: Research Source Type: clinical trials